Full-Time
Senior Director
Lexeo Therapeutics
51-200 employees
Gene therapy for cardiac, neurological diseases
Compensation Overview
$264.5k - $330k/yr
New York, NY, USA
Hybrid
Two days on-site per week in the New York City office; three days working from home.
Master's, PhD
 Biology & Biotech (1) |
|---|
Get referred to Lexeo Therapeutics
See people who can refer or advise you
- A relevant clinical or biomedical Ph.D., or a relevant Pharmacy, Nursing, or MSc/MRes degree.
- At least 10 years of exposure to drug development and real world medical research experience within the biopharmaceutical industry; candidates with only academic experience may be considered.
- Excellent knowledge of clinical trial design, statistics, and data review tools.
- Significant experience in developing protocols and case report forms.
- Ability to share scientific data effectively across functions and through presentations.
- Significant experience reviewing and analyzing clinical trial data to identify potential safety and efficacy trends.
- Experience in health economics and outcomes research, including payer-relevant models.
- Working knowledge of ICH and FDA Good Clinical Practice Guidelines.
- Experience with clinical studies, research collaborations, and real world data assessments and use.
- Demonstrated ability to think analytically and strategically, work independently, and solve problems.
- Publications in peer-reviewed journals for real world evidence and/or health economics and outcomes research.
- Excellent communication and interpersonal relationship skills, including negotiating and relationship management skills across multiple functions and with external vendors.
- Ability to prioritize tasks to deliver on deadlines in a highly collaborative and collegial work style.
- Patient-focused commitment to understanding patient needs.
- Work in partnership with Medical Affairs, Regulatory, Clinical Development, and relevant internal stakeholders to lead the development and execution of real world evidence strategies, protocol development, analysis plan development, implementation of analyses, interpretation of findings, and dissemination or publication.
- Develop and execute study concepts for natural history of disease assessments supporting business and early- and late-development indications.
- Collaborate with Regulatory and Clinical Development to plan real world studies that can serve as natural history studies or external controls, or support clinical studies for regulatory submissions.
- Provide strategic and executional support for cross-functional real world evidence initiatives, including registries and natural history of disease studies for regulators, payers, and clinicians.
- Contribute to the creation of clinical development strategic plans, clinical trial designs, electronic case report forms, and statistical analysis plans.
- Prepare, or oversee vendor preparation of, data tables, listings, figures, clinical study reports, and clinical submission documents.
- Collaborate with the clinical operations team to oversee protocol feasibility assessments, site identification, review of provider specifications, and vendor evaluation.
- Collaborate with the clinical operations team to review vendor, contract research organization, and site scopes of work, study budgets, and plans or manuals related to study data, interactive voice response systems, and central laboratories.
- Develop internal and external training materials and presentations.
- Review and analyze interim and final clinical trial data, including summarizing potential safety and efficacy trends, for clinical study reports, investigator brochures, and development safety update reports.
- Collaborate with the clinical development physician in strategic planning and conduct of investigator meetings and advisory boards.
- Collaborate with the clinical development physician in preparing abstracts, manuscripts, presentations, and materials for external meetings related to the protocol and/or clinical program.
- Oversee scientific activities outsourced to vendors and clinical research organizations.
- Experience working in global regulatory and pharmacovigilance environments.
- Gene therapy and/or rare disease experience in a biotechnology company.
- Experience with first-in-human clinical trial design, preferably with gene or cell therapy.
- Experience developing real world evidence historical controls and methods.
Lexeo Therapeutics develops gene therapies to treat genetic diseases, focusing on cardiac and neurological conditions. It advances therapies by research, clinical trials, and pursuing commercialization through partnerships and grants. The company collaborates with clinicians and researchers, notably leveraging the Weill Cornell Department of Genetic Medicine, to translate genetic discoveries into treatments. Its goal is to bring gene therapies to patients in need by moving from discovery through trials to market, through end-to-end development.
Company Size
51-200
Company Stage
IPO
Headquarters
New York City, New York
Founded
2018
Get referred to Lexeo Therapeutics
See people who can refer or advise you
Simplify's Take
What believers are saying
- Lexeo started SUNRISE-FA 2 in June 2026, showing execution on registrational timing.
- FDA granted LX2020 RMAT in August 2026, validating early clinical signals.
- Lexeo reported $234.2 million cash at June 30, 2026, funding operations into 2028.
What critics are saying
- LX2006 topline data arrives second half 2027; one clinical stumble resets the 2028 BLA.
- LX2020 still has only ten dosed participants; FDA RMAT does not guarantee approval.
- October 2025 financing and prefunded warrants dilute shareholders before any commercialization revenue exists.
What makes Lexeo Therapeutics unique
- Lexeo pairs cardiac gene therapy with Weill Cornell genetics and J&J Impella delivery, January 2026.
- LX2006 uses an accelerated-approval design with external-control CLARITY-FA, reducing placebo exposure.
- LX2020 targets PKP2 arrhythmogenic cardiomyopathy, a rare niche with few disease-modifying competitors.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 1%1 year growth
↓ -2%2 year growth
↓ -2%Lexeo Therapeutics enrolled the first patient in its SUNRISE-FA 2 pivotal trial for LX2006 in Friedreich ataxia cardiomyopathy in June, with topline data expected in the second half of 2027. The company finalised the trial protocol and statistical analysis plan to support an accelerated approval pathway, with a potential biologics licence application submission planned for the first half of 2028. The FDA granted Regenerative Medicine Advanced Therapy designation to Lexeo's LX2020 programme for PKP2 arrhythmogenic cardiomyopathy in August, based on interim clinical data. The therapy has been well tolerated across ten participants with no clinically significant complement activation. As of 30 June 2026, Lexeo held $234.2 million in cash, cash equivalents, and investments, expected to fund operations into 2028. The company reported a net loss of $25.9 million for the second quarter.
Lexeo Therapeutics to participate in the 2026 RBC Capital Markets Global Healthcare Conference. May 19, 2026 NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) - Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that the Company will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2026 at 2:35 p.m. ET in New York, NY. The event will be webcast live under the News & Events tab in the Investors section of the Company's website. A replay of the webcast will be available on the Lexeo website following the presentation. About Lexeo Therapeutics Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. The company is advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including LX2006 in Friedreich ataxia (FA) cardiomyopathy, LX2020 in plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.
Dr. Laura Sepp-Lorenzino joins Lexeo Therapeutics (LXEO) board and science committee. Filing Impact (Moderate) Filing Sentiment Rhea-AI Filing summary. Lexeo Therapeutics, Inc. appointed Dr. Laura Sepp-Lorenzino to its board of directors effective April 28, 2026. She will serve until the company's 2028 annual meeting of stockholders and has also been named to the company's Science and Technology Committee. Dr. Sepp-Lorenzino brings extensive experience from leadership and scientific roles at multiple biotechnology and pharmaceutical companies and currently leads a consulting firm focused on genomic medicine. Under Lexeo's non-employee director compensation policy, she will receive $40,000 in annual cash compensation and an initial option to purchase 50,000 shares, with future annual option grants of 25,000 shares beginning with the 2027 annual meeting. 8-K event classification. Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Key figures. Appointment date: April 28, 2026 Board term end: 2028 annual meeting Annual cash compensation: $40,000 +3 more Key terms. Non-Employee Director Compensation Policy, indemnification agreement, Item 404(a) of Regulation S-K, Science and Technology Committee, +1 more 04/30/2026 - 04:00 AM Faq. What did Lexeo Therapeutics (LXEO) announce in this 8-K filing? Lexeo Therapeutics announced the appointment of Dr. Laura Sepp-Lorenzino to its board of directors, effective April 28, 2026. She will serve until the 2028 annual meeting and join the Science and Technology Committee, bringing extensive genomic medicine and biopharmaceutical leadership experience. Who is Dr. Laura Sepp-Lorenzino, the new Lexeo Therapeutics (LXEO) director? Dr. Laura Sepp-Lorenzino is a biochemist and industry leader who has held senior roles at Intellia Therapeutics, Vertex Pharmaceuticals, Alnylam Pharmaceuticals, and Merck. She now leads GNMmeds LLC and serves on several biotech boards, adding deep genomic medicine and RNA therapeutics expertise to Lexeo. What compensation will Dr. Sepp-Lorenzino receive as a Lexeo Therapeutics (LXEO) director? Under Lexeo's non-employee director compensation policy, Dr. Sepp-Lorenzino will receive $40,000 in annual cash compensation for board service. She also received an initial stock option for 50,000 shares and is eligible for future annual option grants of 25,000 shares, subject to policy terms. When will Dr. Sepp-Lorenzino receive annual equity grants from Lexeo Therapeutics (LXEO)? Annual option grants of 25,000 shares begin with the 2027 annual meeting of stockholders. Because her appointment date is within six months of the 2026 annual meeting, the policy makes her ineligible for an annual grant tied to the 2026 meeting, delaying recurring awards until 2027. Does Dr. Sepp-Lorenzino have any related-party transactions with Lexeo Therapeutics (LXEO)? Other than Lexeo's standard indemnification agreement, the company states Dr. Sepp-Lorenzino has no direct or indirect material interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K, and no such transactions are currently proposed, limiting potential related-party concerns. Are there special arrangements behind Dr. Sepp-Lorenzino's appointment to Lexeo Therapeutics (LXEO)? Lexeo states there are no arrangements or understandings with any persons under which Dr. Sepp-Lorenzino was appointed as director, and no family relationships with existing directors or executive officers. This indicates a standard, independent board appointment process consistent with typical corporate governance practice. Filing exhibits & attachments. 1 document
Lexeo Therapeutics announces research collaboration to explore targeted cardiac delivery of AAV gene therapy. Collaboration will combine Lexeo expertise in cardiac genetic medicine with Johnson & Johnson's expertise in cardiovascular therapeutics and circulatory technologies, including Impella(TM) heart pumps NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) - Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced a research collaboration with Johnson & Johnson, a global leader in cardiovascular health, to investigate localized cardiac delivery of gene therapy. The collaboration seeks to advance the potential efficacy and safety profile of gene therapy for genetically mediated cardiovascular diseases by concentrating AAV (adeno associated viral) delivery to the heart by investigating cutting-edge routes of administration using Impella(TM) heart pump technology. Impella heart pumps provide direct cardiac unloading to enhance myocardial perfusion, which may help delivery of gene therapy. "This collaboration represents an exciting step toward unlocking the full potential of cardiac gene therapy," said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics. "By concentrating delivery to the heart with localized routes of administration leveraging Impella heart pumps, we aim to substantially reduce required AAV doses and improve gene therapy safety while maximizing transgene expression and clinical efficacy. We are thrilled to pair Lexeo's leadership in cardiac genetic medicine with Impella's world-class technology to advance a next generation of targeted genetic medicines for cardiovascular disease." About Lexeo Therapeutics Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. The Company is advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, LX2020 for the treatment of plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need. Cautionary Note Regarding Forward-Looking Statements Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, Lexeo's expectations regarding the partnership and potential of genetic medicines to treat cardiac diseases. Words such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "design," "estimate," "predict," "potential," "develop," "plan" or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Lexeo believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements. These forward-looking statements are based upon current information available to the company as well as certain estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Lexeo's filings with the U.S. Securities and Exchange Commission (SEC)), many of which are beyond the company's control and subject to change. Actual results could be materially different from those indicated by such forward-looking statements as a result of many factors, including but not limited to: risks and uncertainties related to global macroeconomic conditions and related volatility; expectations regarding the initiation, progress, and expected results of Lexeo's preclinical studies, clinical trials and research and development programs; the unpredictable relationship between preclinical study results and clinical study results; delays in submission of regulatory filings or failure to receive regulatory approval; liquidity and capital resources; and other risks and uncertainties identified in Lexeo's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the SEC on November 5, and subsequent future filings Lexeo may make with the SEC. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Lexeo claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Lexeo expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law. Media Response: [email protected] Investor Response: Ashley Kaplowitz [email protected]
Lexeo Therapeutics to present at the 44th Annual J.P. Morgan Healthcare Conference. December 22, 2025 07:30 ET | Source: Lexeo Therapeutics NEW YORK, Dec. 22, 2025 (GLOBE NEWSWIRE) - Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 7:30 AM PT in San Francisco, California. The event will be webcast live under the News & Events tab in the Investors section of the Company's website. A replay of the webcast will be available on the website following the presentation. About Lexeo Therapeutics Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. The Company is advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, LX2020 for the treatment of plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.